共 11 条
- [1] Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) : 2408 - 2417Druker, Brian J.Guilhot, FrancoisO'Brien, Stephen G.Gathmann, InsaKantarjian, HagopGattermann, NorbertDeininger, Michael W. N.Silver, Richard T.Goldman, John M.Stone, Richard M.Cervantes, FranciscoHochhaus, AndreasPowell, Bayard L.Gabrilove, Janice L.Rousselot, PhilippeReiffers, JosyCornelissen, Jan J.Hughes, TimothyAgis, HermineFischer, ThomasVerhoef, GregorShepherd, JohnSaglio, GiuseppeGratwohl, AloisNielsen, Johan L.Radich, Jerald P.Simonsson, BengtTaylor, KerryBaccarani, MicheleSo, CharleneLetvak, LaurieLarson, Richard A.
- [2] Survival benefit with imatinib mesylate versus interferon-α-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia[J]. BLOOD, 2006, 108 (06) : 1835 - 1840Kantarjian, Hagop M.Talpaz, MosheO'Brien, SusanJones, DanielGiles, FrancisGarcia-Manero, GuillermoFaderl, StefanRavandi, FarhadRios, Mary BethShan, JianqinCortes, Jorge
- [3] Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (03) : 232 - 238Marin, DavidIbrahim, Amr R.Lucas, ClaireGerrard, GarethWang, LihuiSzydlo, Richard M.Clark, Richard E.Apperley, Jane F.Milojkovic, DraganaBua, MarcoPavlu, JiriPaliompeis, ChristosReid, AlistairRezvani, KatayounGoldman, John M.Foroni, Letizia
- [4] Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (14) : 2381 - 2388Marin, DavidBazeos, AlexandraMahon, Francois-XavierEliasson, LinaMilojkovic, DraganaBua, MarcoApperley, Jane F.Szydlo, RichardDesai, RittiKozlowski, KasiaPaliompeis, ChristosLatham, VictoriaForoni, LetiziaMolimard, MathieuReid, AlistairRezvani, Katyde Lavallade, HuguesGuallar, CristinaGoldman, JohnKhorashad, Jamshid S.
- [5] European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor[J]. BLOOD, 2008, 112 (12) : 4437 - 4444Marin, DavidMilojkovic, DraganaOlavarria, EduardoKhorashad, Jamshid S.de lavallade, HuguesReid, Alistair G.Foroni, LetiziaRezvani, KatayounBua, MarcoDazzi, FrancescoPavlu, JiriKlammer, MatthiasKaeda, Jaspal S.Goldman, John M.Apperley, Jane F.
- [6] Active transport of imatinib into and out of cells: implications for drug resistance[J]. BLOOD, 2004, 104 (12) : 3739 - 3745Thomas, JWang, LHClark, REPirmohamed, M
- [7] Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) : 258 - 264Wang, L.Giannoudis, A.Lane, S.Williamson, P.Pirmohamed, M.Clark, R. E.
- [8] Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity[J]. BLOOD, 2007, 110 (12) : 4064 - 4072White, Deborah L.Saunders, Verity A.Dang, PhuongEngler, JaneVenables, AmityZrim, StephanieZannettino, AndrewLynch, KevinManley, Paul W.Hughes, Timothy
- [9] OCT-1-mediated influx is a key determinant of the intraceflular uptake of imatinib but not nilotinib, (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib[J]. BLOOD, 2006, 108 (02) : 697 - 704White, Deborah L.Saunders, Verity A.Dang, PhuongEngler, JaneZannettino, Andrew C. W.Cambareri, Antony C.Quinn, Steven R.Manley, Paul W.Hughes, Timothy P.
- [10] Classification of Patients With Chronic Myeloid Leukemia on Basis of BCR-ABL Transcript Level at 3 Months Fails to Identify Patients With Low Organic Cation Transporter-1 Activity Destined to Have Poor Imatinib Response[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (10) : 1144 - 1145White, Deborah L.Hughes, Timothy P.